The Elliot's Neurological Specialties clinic combines medical treatments to slow MS progression with holistic approaches to ...
New MS treatments target myelin repair, neuroprotection, and CNS-resident immune cells, offering hope for progressive forms of the disease. Bruton tyrosine kinase inhibitors (BTKis) like tolebrutinib ...
Hosted on MSN
Biomarker provides clear criteria for choice of treatment options in multiple sclerosis
Treatment with interferon or with glatiramer acetate? This question arises for many patients who receive a diagnosis of multiple sclerosis (MS) for the first time. Until now, the choice between the ...
Medicare drug plans are increasingly excluding coverage of new specialty drugs that treat complex conditions like cancers and autoimmune diseases. New research from the USC Schaeffer Center shows how ...
Prof Nicholas Schwab and his colleagues found a biomarker which allows to tell in advance if therapy with glatirameracetate will be efficient in an individual MS patent. Treatment with interferon or ...
Hosted on MSN
Multiple sclerosis medication gap: Study finds women less likely than men to receive drugs
Women are less likely than men to receive drugs for multiple sclerosis (MS) between the ages of 18 to 40, during women's childbearing years, even when those drugs have been shown to be safe for use ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results